Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
2001 1
2003 1
2005 2
2009 1
2010 1
2013 1
2018 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Akerley W, et al. Cancer. 2003 May 15;97(10):2480-6. doi: 10.1002/cncr.11375. Cancer. 2003. PMID: 12733147 Free article. Clinical Trial.
BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naive, advanced-stage non-small cell lung carcinoma (NSCLC). …
BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of pa …
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicoló G, Perdelli L, Stampino CG, Rosso R, Puntoni R. Ardizzoni A, et al. Cancer. 2001 Oct 1;92(7):1896-904. Cancer. 2001. PMID: 11745263
However, the prognostic role of serum HER-2/neu oncoprotein, particularly in patients with advanced lung carcinoma, remains unknown. This study was designed to assess the potential value of measuring serum levels of HER-2/neu oncoprotein in predicting respons …
However, the prognostic role of serum HER-2/neu oncoprotein, particularly in patients with advanced lung carcinoma, rem …
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Fournel L, et al. Cancer Chemother Pharmacol. 2020 Oct;86(4):497-505. doi: 10.1007/s00280-020-04142-9. Epub 2020 Sep 16. Cancer Chemother Pharmacol. 2020. PMID: 32936316
Herein, we evaluated the impact of Nivolumab on crude and normalized pulmonary artery diameter (PAD). METHODS: We analyzed clinical, morphometric, pathological and radiological data of lung cancer patients treated by Nivolumab in an 18-month period. ...Correlation between …
Herein, we evaluated the impact of Nivolumab on crude and normalized pulmonary artery diameter (PAD). METHODS: We analyzed clinical, …
Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment.
Wolny-Rokicka EI, Wydmański J, Tukiendorf A, Mróz P, Zembroń-Łacny A. Wolny-Rokicka EI, et al. Med Sci Monit. 2018 Nov 27;24:8577-8582. doi: 10.12659/MSM.910280. Med Sci Monit. 2018. PMID: 30479323 Free PMC article.
MATERIAL AND METHODS Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. ...
MATERIAL AND METHODS Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had under …
The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F, Duranyildiz D, Oguz H, Camlica H, Oral EN, Yasasever V, Topuz E. Tas F, et al. Med Oncol. 2005;22(2):139-43. doi: 10.1385/MO:22:2:139. Med Oncol. 2005. PMID: 15965276
The present study was conducted to investigate the value of serum Bcl-2 levels in advanced lung cancer patients. Fifty patients with advanced lung carcinoma pathologically verified and 18 healthy controls were investigated. ...
The present study was conducted to investigate the value of serum Bcl-2 levels in advanced lung cancer patients. Fifty patients with adva …
Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma.
Kato M, Goto S, Soma G. Kato M, et al. Anticancer Res. 2010 Aug;30(8):3125-8. Anticancer Res. 2010. PMID: 20871030
However, after decreasing the dose of GC because of gastrointestinal bleeding caused by the high-dose treatment, there was no response on restarting GC plus LAK cell therapy. The clinical course of this case strongly suggests that local inflammation in the vicinity of tumo …
However, after decreasing the dose of GC because of gastrointestinal bleeding caused by the high-dose treatment, there was no response on re …
Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.
Hayashi M, Sekikawa A, Saijo A, Takada W, Yamawaki I, Ohkawa S. Hayashi M, et al. Anticancer Res. 2005 May-Jun;25(3c):2435-8. Anticancer Res. 2005. PMID: 16080471 Free article.
Although removal of the primary tumor usually resolves this syndrome, effective treatment in patients with advanced lung carcinoma has not been established. Recently, an orally active, selective epidermal growth factor receptor tyrosine kinase (EGFR) inhibito …
Although removal of the primary tumor usually resolves this syndrome, effective treatment in patients with advanced lung ca …
Clinical correlates of in vitro effect of adriamycin on advanced lung carcinoma.
Mattern J, Kaufmann M, Wayss K, Volm M. Mattern J, et al. Klin Wochenschr. 1976 Jul 15;54(14):665-70. doi: 10.1007/BF01469146. Klin Wochenschr. 1976. PMID: 979067
The effect of 1.38 X 10(-5) M adriamycin on tritiated uridine incorporation was studied after 3 hours treatment of suspensions of 25 advanced human lung carcinomas in vitro. The results were correlated with the responses to clinical therapy. All tumours which showed an inh …
The effect of 1.38 X 10(-5) M adriamycin on tritiated uridine incorporation was studied after 3 hours treatment of suspensions of 25 advance …